Hamilton Wealth LLC Sells 37,907 Shares of Moderna, Inc. (NASDAQ:MRNA)

Hamilton Wealth LLC lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 52.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,294 shares of the company’s stock after selling 37,907 shares during the quarter. Moderna comprises 1.1% of Hamilton Wealth LLC’s holdings, making the stock its 26th biggest position. Hamilton Wealth LLC’s holdings in Moderna were worth $3,654,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRNA. Ogorek Anthony Joseph NY ADV acquired a new position in shares of Moderna in the 4th quarter valued at $27,000. Arlington Trust Co LLC increased its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the period. Cedar Wealth Management LLC raised its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of Moderna during the first quarter worth about $32,000. Finally, Rise Advisors LLC boosted its position in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on MRNA shares. Evercore ISI restated an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Barclays dropped their target price on Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $126.59.

Insider Activity

In other news, President Stephen Hoge sold 255 shares of Moderna stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the transaction, the president now owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO James M. Mock sold 648 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 255 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the sale, the president now owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 396,239 shares of company stock worth $55,563,937. Corporate insiders own 15.70% of the company’s stock.

Moderna Trading Down 8.1 %

NASDAQ MRNA traded down $7.59 during trading on Friday, hitting $86.58. The stock had a trading volume of 10,332,912 shares, compared to its average volume of 3,496,157. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $33.18 billion, a PE ratio of -5.53 and a beta of 1.67. The firm has a 50 day moving average price of $129.81 and a 200 day moving average price of $115.02. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period in the prior year, the firm earned ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.